Your browser is no longer supported. Please, upgrade your browser.
IMV IMV Inc. daily Stock Chart
IMV Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own7.80% Shs Outstand60.45M Perf Week-6.82%
Market Cap173.50M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float54.73M Perf Month31.65%
Income- PEG- EPS next Q- Inst Own19.53% Short Float0.65% Perf Quarter-10.31%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.11 Perf Half Y3.24%
Book/sh0.19 P/B15.43 EPS next Y- ROA- Target Price- Perf Year-19.83%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.35 - 5.12 Perf YTD-1.03%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.92% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low112.59% ATR0.33
Employees62 Current Ratio- Sales Q/Q750.00% Oper. Margin- RSI (14)52.86 Volatility8.59% 12.51%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.38 Prev Close2.96
ShortableYes LT Debt/Eq- EarningsMay 15 BMO Payout- Avg Volume322.12K Price2.87
Recom- SMA20-0.07% SMA5026.77% SMA2000.98% Volume445,218 Change-3.04%
May-18-20Upgrade Wells Fargo Equal Weight → Overweight
Apr-01-20Downgrade B. Riley FBR Buy → Neutral $7 → $3
Feb-25-20Downgrade Wells Fargo Overweight → Equal Weight
Jan-28-20Initiated BTIG Research Buy $8
Jan-21-20Upgrade Wells Fargo Equal Weight → Overweight
Nov-26-19Initiated Oppenheimer Outperform
Oct-28-19Initiated Wells Fargo Market Perform
May-29-19Initiated B. Riley FBR Buy
Mar-25-19Initiated H.C. Wainwright Buy $11.50
May-29-20 08:05AM  
May-21-20 07:05AM  
May-15-20 08:25AM  
May-07-20 12:30PM  
May-04-20 07:05AM  
Apr-30-20 07:10AM  
Apr-21-20 05:05PM  
Apr-04-20 08:13AM  
Mar-30-20 05:05PM  
Mar-25-20 07:05AM  
Mar-19-20 11:58AM  
Mar-18-20 10:00AM  
Mar-12-20 12:30PM  
Mar-03-20 03:00PM  
Feb-25-20 08:28AM  
Feb-20-20 07:05AM  
Feb-14-20 07:05AM  
Feb-04-20 07:05AM  
Feb-03-20 09:34AM  
Jan-31-20 07:05AM  
Jan-24-20 07:05AM  
Jan-01-20 12:14PM  
Dec-19-19 02:45PM  
Dec-08-19 12:05PM  
Nov-27-19 07:05AM  
Nov-08-19 08:35AM  
Nov-07-19 07:30AM  
Nov-06-19 09:01AM  
Nov-05-19 08:01AM  
Nov-04-19 09:45AM  
Nov-01-19 10:30AM  
Oct-30-19 07:05AM  
Oct-29-19 07:05AM  
Oct-16-19 10:01AM  
Oct-11-19 07:05AM  
Oct-04-19 07:23AM  
Sep-30-19 03:00AM  
Sep-23-19 07:05AM  
Sep-04-19 07:52AM  
Aug-22-19 07:05AM  
Aug-08-19 05:05PM  
Aug-02-19 10:30AM  
Jul-26-19 04:00PM  
Jul-25-19 03:22PM  
Jun-13-19 05:08PM  
Jun-12-19 07:05AM  
Jun-04-19 07:05AM  
Jun-01-19 02:15PM  
May-16-19 07:05AM  
May-14-19 05:05PM  
May-10-19 10:18AM  
May-09-19 05:05PM  
May-08-19 07:05AM  
May-03-19 07:05AM  
Apr-26-19 07:05AM  
Apr-18-19 07:05AM  
Apr-16-19 09:31AM  
Apr-04-19 07:05AM  
Apr-03-19 08:00AM  
Mar-26-19 07:05AM  
Mar-25-19 07:05AM  
Mar-21-19 05:05PM  
Mar-18-19 07:05AM  
Mar-12-19 07:05AM  
Mar-11-19 08:41AM  
Mar-08-19 07:05AM  
Mar-07-19 07:05AM  
Mar-06-19 09:15AM  
Mar-01-19 10:02AM  
Feb-28-19 04:51PM  
Jan-29-19 07:05AM  
Jan-28-19 04:35PM  
Jan-17-19 07:05AM  
Dec-13-18 04:05AM  
Dec-10-18 07:05AM  
Dec-05-18 07:05AM  
Nov-26-18 04:35PM  
Nov-20-18 07:05AM  
Nov-16-18 08:10AM  
Nov-15-18 07:05AM  
Nov-06-18 07:05AM  
Nov-02-18 07:05AM  
Oct-23-18 07:05AM  
Oct-09-18 07:05AM  
Sep-27-18 07:05AM  
Sep-18-18 07:05AM  
Sep-11-18 07:05AM  
Sep-04-18 05:50PM  
IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.